MARKET

GILD

GILD

Gilead Sciences Inc
NASDAQ
140.30
+0.93
+0.67%
After Hours: 141.57 +1.27 +0.90% 19:06 04/01 EDT
OPEN
139.69
PREV CLOSE
139.37
HIGH
141.49
LOW
138.82
VOLUME
5.29M
TURNOVER
--
52 WEEK HIGH
156.40
52 WEEK LOW
90.95
MARKET CAP
174.14B
P/E (TTM)
20.69
1D
5D
1M
3M
1Y
5Y
1D
Lilly CEO says company opposes codification of Trump drug pricing deals
Seeking Alpha · 2h ago
Gilead Extends Deadline on Tender Offer to Acquire Arcellx
Dow Jones · 3h ago
Gilead extends Arcellx tender offer expiration date
Seeking Alpha · 3h ago
*Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD
Dow Jones · 3h ago
*Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD
Dow Jones · 3h ago
Gilead Sciences Extends Expiration Of Tender Offer From April 2 To April 24 To Acquire Arcellx At $115/Share
Benzinga · 3h ago
Gilead extends Arcellx tender offer deadline to April 24
Reuters · 3h ago
GILEAD - TENDER OFFER EXPIRATION EXTENDED TO 5:00 P.M. ET ON APRIL 24, 2026
Reuters · 3h ago
More
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.

Webull offers Gilead Sciences Inc stock information, including NASDAQ: GILD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GILD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GILD stock methods without spending real money on the virtual paper trading platform.